



May 15, 2025

BSE Limited

The Listing Department
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Fort, Mumbai 400 001
Maharashtra, India

BSE Scrip Code: 544309

National Stock Exchange of India Limited

The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Maharashtra, India

NSE Symbol: IKS

Dear Sir/Ma'am,

Sub: Press Release – Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2025.

Press Release in respect of Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2025 is enclosed herewith.

Request you to take it on record and disseminate it on your website.

Thanking you.

Yours sincerely,

For **Inventurus Knowledge Solutions Limited**

Sameer Chavan

Company Secretary and Compliance Officer

Membership No. F7211

Encl: As above

PRESS RELEASE

IKS Health Delivers Strong Q4 FY25 Performance with 17% YoY Revenue and 133% YoY PAT Growth

- Revenue growth in Q4 17% YoY in INR, 13% YoY in USD
- Q4 EBITDA up 68% YoY; 13% QoQ
- PAT up 133% growth YoY; 14% QoQ
- Adjusted PAT up 108% YoY; 13% QoQ

India | May 15, 2025: Inventurus Knowledge Solutions Limited (NSE: IKS), a technology enabled healthcare solutions provider highlights strong growth in Q4 FY25. Widely recognized as IKS Health, a care enablement platform assisting physician enterprises with concentrated focus in the US, announced its financial results for the quarter ended March 31, 2025.

	Q4FY25 (INR mn)	FY25 (INR mn)
Revenue	7,240	26,640
PAT	1,478	4,861
EBITDA	2,262	7,911
Adjusted PAT	1,646	5,504

*“The results for the quarter reflect the strength of our business where we have delivered industry leading revenue growth owing to ramp up of new clients and continuous margin improvement as we continue to transform the business using technology and global human capital. Our Q4 FY25 EBITDA margins have crossed 31%, a significant improvement from the 24% proforma margin of FY2024,” said **Sachin K. Gupta, Founder & CEO, IKS Health.** “The last quarter saw five prominent client wins including three platform deals which gives us the confidence in our strategy of building the full breadth of our platform in a market that largely consists of point solutions companies.”*



Nithya Balasubramanian, CFO, IKS Health said, *“We have delivered a very healthy margin and strong revenue growth of 17% YoY and 10% QoQ despite some compression in revenue as we focus on the right set of customers and globalize the legacy AQuity workforce. Ongoing investments in technology and AI will remain central to our strategy for achieving excellence in outcomes and client satisfaction.”*

Key Financial Highlights: FY 25 ended on March 31, 2025

- Revenue at ₹26,640 million (47% YoY)
- EBITDA at ₹7,911 million (50% YoY)
- PAT at ₹4,861 million (31% YoY)
- Adjusted PAT at ₹5,504 (39% YoY)

Business Highlights:

Our Q4 deal wins demonstrate strong momentum toward full platform engagements (3 out of 5 deals) - both in new initiatives and expansions of existing programs—reflecting growing client confidence in IKS Health’s ability to deliver on the vision of an integrated care enablement platform.

- **Sky Lakes:** Strategic partnership to deliver outstanding care and ensure financial sustainability across hospital and clinical settings
- **Western Washington Medical Group:** Expanded partnership to implement the IKS care enablement platform to enhance care delivery, improve financial outcomes and invest in growth
- **GI Alliance:** Strategic partnership to optimize clinical and financial processes through the IKS care enablement platform to deliver high quality care and accelerate growth
- **Platinum Dermatology Partners:** Expanded partnership to implement IKS Health care enablement platform
- **OrthoNY:** Expanded alliance to cover patient engagement hub and revenue cycle management to deploy AI-powered personalized digital strategies to deliver exceptional patient experience

Industry Recognition & Awards

- IKS Health received 3 notable recognitions in Black Book Research 2025 Rankings:
 - Won Top honors in the newly launched AI-driven Revenue Cycle Management (RCM) category
 - Ranked #1 in Clinical Documentation for the 12th consecutive year
 - Ranked #1 in Medical Coding for the 3rd year in a row



- Ranked Best in KLAS for Medical Transcription Services for 2025
- Earned HITRUST r2 Certification demonstrating that IKS has met the demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.

Safe Harbour

Certain statements in this release concerning our future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. It is not possible to undertake to update any such statement that may have been made from time to time.

About IKS Health

IKS Health takes on the chores of healthcare—spanning administrative, clinical, and operational burdens—so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS enables stronger, financially sustainable enterprises. IKS's Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS's global workforce supports large health systems across the United States. For more information, visit ikshealth.com.

Inventurus Knowledge Solutions Limited was listed on National Stock Exchange of India Limited (NSE) and BSE Limited (Bombay Stock Exchange) on December 19, 2024. {Scrip codes: NSE - IKS and BSE - 544309}

MEDIA CONTACT - IKS HEALTH	INVESTOR RELATIONS CONTACT - IKS HEALTH
Srushti Rao	Saransh Mundra
Vice President - Communications	Head - Investor Relations
srushti.rao@ikshealth.com	investor_relations@ikshealth.com